Amgen stock steadies above $430 after Q2 2026 beat and higher outlook
Published on 08/31/2026 at 07:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen Inc. (US0311621009) stock is trading above $430 following a second-quarter 2026 earnings beat and a higher full-year outlook that have reinforced confidence in the biotech company’s profit trajectory as of August 28, 2026.
Q2 2026 earnings beat with double-digit growth
Per the latest Q2 2026 update, Amgen reported revenue of $10.05 billion in the second quarter of 2026, which marked a 9.5 percent increase compared with the same period a year earlier and exceeded analyst expectations of $9.43 billion for the quarter. The Q2 2026 coverage highlighted that the earnings performance was driven by broad-based growth across Amgen’s portfolio and supported by operational leverage.
In terms of profitability, Amgen’s reported earnings per share in Q2 2026 came in at $6.29, which was $0.67 above the consensus estimate cited for the quarter. The same Q2 2026 report emphasized that this earnings beat combined with revenue expansion indicates that Amgen is delivering growth both at the top line and in its earnings base, a combination that often matters for investors evaluating sustainability of returns.
Raised 2026 EPS outlook supports valuation
Alongside the Q2 2026 numbers, Amgen reaffirmed and effectively raised confidence in its guidance for the 2026 full year, indicating an expected earnings per share range of $22.30 to $23.50. That guidance coverage described the EPS band as a key signal for investors, as it implies continued double-digit growth relative to the current quarterly run rate and frames expectations for margins and cash generation over the rest of the year.
The comparison between the Q2 2026 EPS of $6.29 and the mid-point of the 2026 guidance range near $22.90 suggests that management anticipates a solid continuation of earnings momentum in the coming quarters. From a quantitative perspective, the Q2 EPS represents roughly 27 percent of the mid-point of the full-year range, implying room for further growth as subsequent quarters accumulate toward the target. For investors, this relationship between the latest quarterly performance and the guided full-year band can be an anchor for assessing whether the current share price multiple on expected earnings is justified.
Share price, moving averages and market cap
On the market side, Amgen stock closed at $432.42 on August 28, 2026 in New York, which placed the shares above both the 50-day moving average of $388.64 and the 200-day moving average of $364.71 at that date. A recent corporate-news summary noted that this positioning above key moving averages underscores a strong medium-term uptrend that has developed alongside the company’s improving earnings profile.
Market data for the same session showed Amgen at $432.42 with an intraday high of $437.89 and a low of $430.72, while the daily change was a decline of $4.57, or 1.05 percent, on trading volume of 1.74 million shares as of August 28, 2026. A stock quote overview listed Amgen’s broader market statistics, including a market capitalization of $233.78 billion, placing the company among the larger constituents of major US equity benchmarks and highlighting its scale within the global biopharmaceutical sector.
Further market statistics indicate that Amgen shares have delivered notable performance over different periods leading into late August 2026. A market-cap ranking list showed Amgen at a price of $432.42 with a one-day change of negative 1.05 percent and a five-day performance of negative 1.57 percent, while the 10-day performance was a gain of 4.75 percent, the 20-day performance a gain of 12.93 percent, the 60-day performance a gain of 28.60 percent, the 120-day performance a gain of 16.25 percent, and the 250-day performance a gain of 54.47 percent. The same data set indicated that the year-to-date performance for Amgen as of late August 2026 stood at 34.82 percent, which underlines how the stock has significantly outperformed many broad-market measures over the preceding months.
Operational strength and investor implications
The combination of revenue growth, earnings outperformance and an affirmed 2026 EPS guidance range paints a picture of operational strength for Amgen in its latest reported quarter. The 9.5 percent revenue increase to $10.05 billion in Q2 2026 versus the prior year’s quarter and the overshoot relative to the $9.43 billion analyst forecast give a concrete indication that demand for Amgen’s therapies and products remains robust, supporting volume and pricing dynamics. Meanwhile, the EPS beat of $0.67 over expectations evidences cost discipline and margin resilience, important attributes for a mature biopharmaceutical name managing a diversified portfolio and significant research and development investment.
For investors, the raised confidence in the 2026 EPS range of $22.30 to $23.50 can serve as a key reference point in evaluating valuation. At a share price of $432.42, the implied price-to-earnings multiple on the mid-point of the guided range is just under 19 times, using the approximate mid-point of $22.90 as the denominator. This comparison between price and expected earnings, grounded in the current guidance, gives a numerical framework for understanding how the market is pricing Amgen’s growth prospects, risk profile and cash flow generation over the near term.
Representative product and pipeline context
Among Amgen’s broad set of biopharmaceutical offerings, a representative product that often features in discussions about the company’s earnings base is its class of biologic therapies addressing serious conditions such as cardiovascular disease and oncology. In the context of Q2 2026 and the raised 2026 EPS guidance, the performance of such flagship treatments and the contribution from innovative pipeline additions help underpin the revenue expansion from $9.43 billion in the consensus forecast to the actual $10.05 billion reported. The numerical gain of $0.62 billion over expectations in that quarter highlights how successful commercialization and portfolio management can translate directly into incremental top-line contribution that supports the guidance band.
Closing market view on Amgen stock
As of the close on August 28, 2026, Amgen stock traded at $432.42 on its primary US listing, with a market capitalization of $233.78 billion in USD terms. That price level stood above both the $388.64 50-day moving average and the $364.71 200-day moving average, while year-to-date performance of 34.82 percent and a 250-day gain of 54.47 percent illustrated substantial appreciation over recent months, set against a backdrop of a Q2 2026 earnings beat and a guided full-year EPS range of $22.30 to $23.50 that together frame investor expectations.
Fact box
Company: Amgen Inc.
ISIN: US0311621009
Ticker: AMGN
Exchange: Nasdaq
Price (as of August 28, 2026, 4:00 p.m. ET): $432.42 USD
Market cap: $233.78 billion (as of August 28, 2026)
Sector / Industry: Health care / Biotechnology
Index membership: S&P 500
